IMPAX Laboratories, Inc. (IPXL) Announces The Alignment Of Quality And Manufacturing Operations Under The Leadership Of Jeffrey D. Nornhold

HAYWARD, Calif., April 2, 2014 /PRNewswire/ --Impax Laboratories, Inc.(NASDAQ: IPXL) today announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Company's Senior Vice President, Global Quality Affairs since March 2011.

Impax Laboratories, Inc.
Mark Fitch, Senior Vice President, Global Operations announced his plans to retire, but will continue to work with Nornhold to ensure a smooth transition. Since joining Impax in June of 2011, Fitch has partnered with Nornhold to enhance the Company's manufacturing and quality areas, and improve operating efficiencies. This includes improvements to the Company's Hayward facility, expansion of the Taiwan facility, the transfer of numerous currently approved and manufactured products from Hayward to Taiwan and building a highly qualified leadership team.

"Working alongside Mark the past three years has been a great experience," said Nornhold. "We have collaborated on enhancing and improving the critical areas of quality, manufacturing and compliance."

"Jeff has done an outstanding job of building a highly skilled internal quality organization and establishing the foundation for sustainable quality and compliance", said Larry Hsu, Ph.D., President and CEO of Impax Laboratories. "We believe Jeff is the ideal person to manage this new structure, and effectively drive compliance, efficiencies and collaboration across these key business functions."

Mr. Nornhold has over 24 years of experience in pharmaceutical manufacturing and related technical operations. Prior to joining Impax in 2011, he gained a significant amount of Technical Operations experience at Watson Pharmaceuticals (now Actavis plc), serving as Vice President, Quality Operations - International, and was responsible for manufacturing sites for both dosage and active pharmaceutical ingredients outside of the U.S. He also served as Vice President, U.S. Quality Operations at Watson, leading the development and execution of quality initiatives for all U.S. sites. Prior to joining Watson in 2000, he held numerous leadership positions within the pharmaceuticals industry.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Company Contact:
Mark Donohue
Investor Relations and Corporate Communications
(215) 558-4526
www.impaxlabs.com

Logo - http://photos.prnewswire.com/prnh/20140402/PH96035LOGO

SOURCE Impax Laboratories, Inc.

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.